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INTRODUCTION
Kidney transplantation (KT) has improved patient survival 
and quality of life compared to other modes of renal re-
placement therapy. It has become the treatment of choice 
in end-stage renal failure [1]. However, the gradual decline 
in renal function after transplantation is inevitable [2]. The 
rate may be influenced by numerous variables, including 
both donor- and recipient-related characteristics. Donor 
age, donor and recipient race, cold ischemia time, human 
leukocyte antibody (HLA) mismatching, and delayed graft 
function have all been shown to significantly influence 
short- and long-term graft survival [3-5]. Moreover, a calci-
neurin inhibitor (CNI) based immunosuppression regimens 
exhibit dose-related nephrotoxicity and could be a contrib-
uting factor in graft function decline [6].
Early identification of those patients at risk of graft 
function and subsequent timely therapeutic intervention is 
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necessary to improve outcomes in the kidney transplant 
patients.
Previous studies have shown that the parameters of re-
nal function, mainly serum creatinine, creatinine clearance, 
and glomerular filtration rate (GFR), are valuable indicators 
of long-term outcomes. Early graft function, especially the 
1 year posttransplant graft filtration rate or serum creatine 
level, is the most powerful predictor of long-term graft 
and patient survival [7-9]. However, these studies included 
patients who were treated in the early period of the trans-
plantation era. Thus, the studies did not consider highly 
sensitized patients, ABO-incompatible transplantations, 
and marginal deceased donor.
After 2000, the number of kidney transplants of high 
immunologic risk patients (e.g., highly sensitized recipi-
ents, leucocyte cross-matching positive, and ABO-incom-
patible transplantation) and deceased donor transplanta-
tion, including marginal donors, rapidly increased in Korea. 
Special pretransplant and early posttransplantation man-
agement regimens were developed, such as plasmaphere-
sis for antibody filtration and use of rituximab for antibody 
depletion [10]. At the same time, new immunosuppressive 
agents were rapidly developed [11,12].
Given the recent changes, early graft stabilization af-
ter transplantation is essential. Therefore, we evaluated 
the effect of early graft stabilization on long-term graft 
survival and functional status using the databases from a 
large-volume KT center.
METHODS
We accessed the data of 1,976 consecutive KT recipients 
between 2005 and 2018 performed at Severance Hospital, 
Korea. We identified 1,895 cases that met our inclusion cri-
teria. We excluded the following cases: graft failure within 
1 month (n=9), loss to follow-up (n=2), pediatric recipient 
or donor (age under 18 years old, n=37), or combined or-
gan transplantation (n=33). We categorized the included 
patients into four groups defined by quartiles (Q) of serum 
creatinine levels at 1-month posttransplant. The cut points 
for the groups were 1.0 mg%, 1.23 mg%, and 1.52 mg%. 
We used CNI based triple regimen (mycophenolate mofetil, 
steroid) as an immunosuppressants protocol, and after 6 
months, steroid withdrawal is considered. 
Our purpose of this study was comparing of graft sur-
vival of each group and comparing graft function and fail-
ure rate. Graft function was measured by estimated GFR 
by Modification of Diet in Renal Disease equation. Graft 
failure was defined as returning to dialysis or renal retrans-
plantation. Categorical variables are presented as frequen-
cies. We used the chi-square test or Fisher’s exact test to 
evaluate these data. Time-to-event data were compared 
by Kaplan-Meier survival curves with log-rank tests. For 
the adjusted model, we used a Cox regression analysis. All 
analyses were performed using standard statistical soft-
ware (IBM SPSS ver. 25.0; IBM Corp., Armonk, NY, USA) 
and P<0.05 was considered statistically significant.
RESULTS
We had 450 individuals in the 1st Q (serum creatinine <1.0 
mg%), 476 in the 2nd Q (serum creatinine <1.23 mg%), 
489 in the 3rd Q (serum creatinine <1.52 mg%), and 480 
HIGHLIGHTS
• One-month posttransplant serum creatinine level is re-
lated to long-term graft function.
• The glomerular filtration rate is associated with graft 
outcome.
• After the year 2000, higher risk kidney transplants in-
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a)
Fig. 1. Mean glomerular filtration rate (GFR) of functioning graft by quan-
tile group of serum creatinine quantile at 1-month posttransplant. Q, quar-
tile. a)P<0.05 vs. each other.
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in the 4th Q (serum creatinine ≥1.52 mg%). With respect 
to high-risk transplantation, there were 582 (30.7%) cases 
of ABO-incompatible transplants and 170 (9.0%) cases of 
retransplantation, including four cases of three transplants 
and one case of four transplants. Finally, 286 (15.1%) 
recipients underwent plasmapheresis at least one time 
(range, 1–7 times).
Serial changes of GFR for each group by year are 
shown in Fig. 1. The 1st Q group showed statistical signif-
icance compared to all other groups each year. Within the 
entire sample, there were 251 graft failure events in the 1st 
Q group with 35 (8.8%) cases, 2nd Q with 54 (11.3%) cas-
es, 3rd Q with 63 (12.9%) case, and 4th Q with 99 (20.6%) 
cases. The graft survival rate of the 1st Q was significantly 
higher than that of all the other groups at posttransplant 
Table 1. Multiple Cox regression analysis for graft failure
Variable B P-value Hazard ratio 95% Confidential interval
Serum creatinine, posttransplant 1 month 0.023
   2nd Q (<1.23 mg%) 0.116 0.606 1.123 0.722–1.748
   3rd Q (<1.52 mg%) 0.220 0.345 1.246 0.790–1.965
   4th Q (≥1.52 mg%) 0.585 0.013 1.795 1.133–2.843
Retransplantation 0.136 0.530 1.146 0.749–1.754
Pretransplant desensitization –0.264 0.461 0.768 0.382–1.547
ABO-incompatible 0.297 0.459 1.346 0.613–2.957
Recipient age (yr) 0.049
   25–34 –0.226 0.512 0.798 0.406–1.568
   35–44 –0.567 0.101 0.567 0.288–1.117
   45–54 –0.326 0.326 0.722 0.377–1.383
   55–64 0.002 0.996 1.002 0.515–1.950
   ≥65 0.255 0.572 1.291 0.533–3.129
Donor age (yr) 0.109
   25–34 –0.017 0.951 0.983 0.567–1.703
   35–44 –0.395 0.167 0.674 0.384–1.180
   45–54 –0.146 0.586 0.864 0.511–1.462
   ≥55 0.148 0.597 1.159 0.670–2.005
Acute rejection within 1 year 0.651 0.000 1.918 1.355–2.715
HLA mismatching, zero-mismatchinga) 0.015
   1–3 Ag mismatching 0.302 0.242 1.352 0.816–2.240
   4–6 Ag mismatching 0.665 0.014 1.944 1.146–3.298
Donor sex, female 0.323 0.016 1.382 1.063–1.796
Recipient sex, female 0.126 0.403 1.134 0.844–1.523
Donor type, living relateda) 0.000
   Living unrelated 0.109 0.579 1.116 0.758–1.643
   Deceased 0.737 0.000 2.089 1.457–2.996
Q, quartile; HLA, human leukocyte antibody.
a)Reference value.



















1st Q (<1.0 mg%)
2nd Q (<1.23 mg%)
3rd Q (<1.52 mg%)
4th Q (>1.52 mg%)
a)
Fig. 2. Graft survival rate by quantile group of serum creatinine quantile 
at 1-month posttransplant. Q, quartile. a)P<0.05 vs. others.
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every year (Fig. 2).
In the multivariate analysis, high serum creatinine 
level at 1-month posttransplant (4th quantile) is an inde-
pendent risk factor for graft failure with a hazard ratio of 
1.799 (P=0.013). Posttransplant 1-month serum creatinine 
(P=0.023), recipient age (P=0.049), HLA zero-mismatching 
(P=0.015), acute rejection within 1 year (P<0.001), and a 
living related donor (P<0.001) were shown to be statistical-
ly significant factors (Table 1). 
DISCUSSION
This study showed that the 1-month posttransplant serum 
creatinine level is a strong predictor of long-term graft 
function for patients who had transplants after 2000. 
Moreover, the results reveal that some classical risk fac-
tors, such as HLA mismatching, donor type, and acute re-
jection within 1 year, affect long-term graft function. As the 
risk of early renal graft failure has substantially decreased 
over recent years, it is more critical to improve long-term 
graft function and the prevention of graft failure. It is also 
essential to find predictors of graft function to optimize 
the posttransplant care plan, including immunosuppres-
sant combinations [13].
Previous studies have shown that 1-year posttransplant 
serum creatinine levels and GFR were strong predictive 
factors of long-term graft outcome [2-4]. However, these 
studies do not reflect the current state of KT as they were 
published one to two decades ago. There have been many 
changes in the transplantation field. High immunologic 
risk transplantation has been successfully performed, in-
cluding ABO-incompatible transplantation. The finding of 
this study that renal and graft failures was not influenced 
by advanced donor age was unexpected and is inconsis-
tent with that of a previous report [14]. A study by De la 
Vega et al. [15] found that kidneys from living donors aged 
50 years or older had a lower GFR pre- and posttransplant. 
Our study showed that only the recipient’s age was related 
to graft failure.
This study is meaningful since it evaluated the long-
term graft function of a substantial study population, in-
cluding high-risk transplant patients (752/1,895, 39.6%). 
However, our study has some limitations. First, this is a ret-
rospective single-institution study. The patient treatment 
protocol, including the immunosuppressive drug regimen, 
has changed during the study period. In summary, the 
1-month posttransplant serum creatinine level is the most 
relevant parameter in predicting long-term graft function. 
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